Residence time of receptor - Ligand complexes and its effect on biological function

Biochemistry

Volumn 47, Issue 20, 2008, Pages 5481-5492

  Tummino, Peter J ^a   Copeland, Robert A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; COMPLEXATION; DRUG PRODUCTS; MOLECULAR INTERACTIONS;

BIOLOGICAL FUNCTION; RECEPTOR-LIGAND COMPLEXES;

LIGANDS;

APREPITANT; ARGATROBAN; CANDESARTAN; CHLORPROMAZINE; CLOZAPINE; DARUNAVIR; DESLORATADINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROMYCIN; FINASTERIDE; GELDANAMYCIN; HALOPERIDOL; HIRUDIN; JOSAMYCIN; LAPATINIB; LEPIRUDIN; LIGAND; LOPINAVIR; MELAGATRAN; NELFINAVIR; PROTEINASE INHIBITOR; QUETIAPINE; RECEPTOR; RITANSERIN; SAXAGLIPTIN; SUFUGOLIX; TELMISARTAN; TRICLOSAN; UNINDEXED DRUG; VILDAGLIPTIN;

ADAPTIVE IMMUNITY; BINDING KINETICS; CLINICAL TRIAL; COMPLEX FORMATION; DNA REPLICATION; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVITY; EQUILIBRIUM CONSTANT; HUMAN; MATHEMATICAL ANALYSIS; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TIME;

BIOLOGY; HUMANS; KINETICS; LIGANDS; PROTEIN BINDING; TIME FACTORS;

EID: 44049103958     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi8002023     Document Type: Review

References (63)

1. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
2. Gupta, P. B., Mani, S., Yang, J., Hartwell, K., and Weinberg, R. A. (2005) The evolving portrait of cancer metastasis. Cold Spring Harbor Symp. Quant. Biol. 70, 291-297.
3. Hetts, S. W. (1998) To die or not to die: An overview of apoptosis and its role in disease. JAMA 279, 300-307.
4. Klionsky, D. J., and Emr, S. D. (2000) Autophagy as a regulated pathway of cellular degradation. Science 290, 1717-1721.
5. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discovery 5, 730-739.
6. Vauquelin, G., and Van Liefde, I. (2006) Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol. Sci. 27, 356-359.
7. Vauquelin, G., Fierens, F., and Van Liefde, I. (2006) Long-lasting angiotensin type 1 receptor binding and protection by candesartan: Comparison with other biphenyl-tetrazole sartans. J. Hypertens. 24, S23-S30.
8. Swinney, D. C. (2006) Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett. Drug Des. Discovery 3, 569-574.
9. Copeland, R. A. (2000) Enzymes. A Practical Introduction to Structure, Mechanism, and Data Analysis, Wiley, New York.
10. Copeland, R. A. (2005) Evaluation of Enzyme Inhibitors in Drug Discovery. A Guide for Medicinal Chemists and Pharmacologists, Wiley, New York.
11. Koshland, D. E. (1958) Application of a Theory of Enzyme Specificity to Protein Synthesis. Proc. Natl. Acad. Sci. U.S.A. 44, 98-104.
12. Van Aller, G. S., Nandigama, R., Petit, C. M., DeWolf, W. E., Jr., Quinn, C. J., Aubart, K. M., Zalacain, M., Christensen, S. B., Copeland, R. A., and Lai, Z. (2005) Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin. Biochemistry 44, 253-260.
13. Halford, S. E. (1971) Escherichia coli alkaline phosphatase. An analysis of transient kinetics. Biochem. J. 125, 319-327.
14. Fersht, A. (1999) Structure and Mechanism in Protein Science, pp 132-168, Freeman, New York.
15. Janin, J., and Chothia, C. (1990) The structure of protein-protein recognition sites. J. Biol. Chem. 265, 16027-16030.
16. Katsamba, P. S., Navratilova, I., Calderon-Cacia, M., Fan, L., Thornton, K., Zhu, M., Bos, T. V., Forte, C., Friend, D., Laird-Offringa, I., Tavares, G., Whatley, J., Shi, E., Widom, A., Lindquist, K. C., Klakamp, S., Drake, A., Bohmann, D., Roell, M., Rose, L., Dorocke, J., Roth, B., Luginbuhl, B., and Myszka, D. G. (2006) Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. Anal. Biochem. 352, 208-221.
17. VanCott, T. C., Bethke, F. R., Polonis, V. R., Gorny, M. K., Zolla-Pazner, S., Redfield, R. R., and Birx, D. L. (1994) Dissociation rate of antibody-gpl20 binding interactions is predictive of V3-mediated neutralization of HIV-I. J. Immunol. 153, 449-459.
18. Foote, J., and Eisen, H. N. (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. U.S.A. 92, 1254-1256.
19. Cho, S., Swaminathan, C. P., Yang, J., Kerzic, M. C., Guan, R., Kieke, M. C., Kranz, D. M., Mariuzza, R. A., and Sundberg, E. J. (2005) Structural basis of affinity maturation and intramolecular cooperativity in a protein-protein interaction. Structure 13, 1775-1787.
20. Guermonprez, P., England, P., Bedouelle, H., and Leclerc, C. (1998) The rate of dissociation between antibody and antigen determines the efficiency of antibody-mediated antigen presentation to T cells. J. Immunol. 161, 4542-4548.
21. Margulies, D. H., Corr, M., Boyd, L. F., and Khilko, S. N. (1993) MHC class I/peptide interactions: Binding specificity and kinetics. J. Mol. Recognit. 6, 59-69.
22. Boniface, J. J., Reich, Z., Lyons, D. S., and Davis, M. M. (1999) Thermodynamics of T cell receptor binding to peptide-MHC: Evidence for a general mechanism of molecular scanning. Proc. Natl. Acad. Sci. U.S.A. 96, 11446-11451.
23. Krogsgaard, M., Prado, N., Adams, E. J., He, X. L., Chow, D. C., Wilson, D. B., Garcia, K. C., and Davis, M. M. (2003) Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol. Cell 12, 1367-1378.
24. Vincent, J. P., and Lazdunski, M. (1972) Trypsin-pancreatic trypsin inhibitor association. Dynamics of the interaction and role of disulfide bridges. Biochemistry 11, 2967-2977.
25. Olson, M. W., Gervasi, D. C., Mobashery, S., and Fridman, R. (1997) Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J. Biol. Chem. 272, 29975-29983.
26. Zhao, H., Bernardo, M. M., Osenkowski, P., Sohail, A., Pei, D., Nagase, H., Kashiwagi, M., Soloway, P. D., DeClerck, Y. A., and Fridman, R. (2004) Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J. Biol. Chem. 279, 8592-8601.
27. Benkovic, S. J., Valentine, A. M., and Salinas, F. (2001) Replisome-mediated DNA replication. Annu. Rev. Biochem. 70, 181-208.
28. Kaboord, B. F., and Benkovic, S. J. (1995) Accessory proteins function as matchmakers in the assembly of the T4 DNA polymerase holoenzyme. Curr. Biol. 5, 149-157.
29. Morris, C. F., Sinha, N. K., and Alberts, B. M. (1975) Reconstruction of bacteriophage T4 DNA replication apparatus from purified components: Rolling circle replication following de novo chain initiation on a single-stranded circular DNA template. Proc. Natl. Acad. Sci. U.S.A. 72, 4800-4804.
30. Yang, J., Zhuang, Z., Roccasecca, R. M., Trakselis, M. A., and Benkovic, S. J. (2004) The dynamic processivity of the T4 DNA polymerase during replication. Proc. Natl. Acad. Sci. U.S.A. 101, 8289-8294.
31. Schrock, R. D., and Alberts, B. (1996) Processivity of the gene 41 DNA helicase at the bacteriophage T4 DNA replication fork. J. Biol. Chem. 271, 16678-16682.
32. Mathews, C. K. (1994) in Molecular Biology of Bacteriophage T4 (Karam, J. D., Ed.) pp 1-8, American Society for Microbiology, Washington, DC.
33. Capson, T. L., Peliska, J. A., Kaboord, B. F., Frey, M. W., Lively, C., Dahlberg, M., and Benkovic, S. J. (1992) Kinetic characterization of the polymerase and exonuclease activities of the gene 43 protein of bacteriophage T4. Biochemistry 31, 10984-10994.
34. Trakselis, M. A., Roccasecca, R. M., Yang, J., Valentine, A. M., and Benkovic, S. J. (2003) Dissociative properties of the proteins within the bacteriophage T4 replisome. J. Biol. Chem. 278, 49839-49849.
35. Chilkoti, A., Boland, T., Ratner, B. D., and Stayton, P. S. (1995) The relationship between ligand-binding thermodynamics and protein-ligand interaction forces measured by atomic force microscopy. Biophys. J. 69, 2125-2130.
36. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860.
37. Dierynck, I., De Wit, M., Gustin, E., Keuleers, L., Vandersmissen, J., Hallenberger, S., and Hertogs, K. (2007) Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J. Virol. 81, 13845-13851.
38. Richman, D. D., Morton, S. C., Wrin, T., Hellmann, N., Berry, S., Shapiro, M. F., and Bozzette, S. A. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18, 1393-1401.
39. De Meyer, S., Azijn, H., Surleraux, D., Jochmans, D., Tahri, A., Pauwels, R., Wigerinck, P., and de Bethune, M. P. (2005) TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49, 2314-2321.
40. Pratley, R. E., and Salsali, A. (2007) Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 23, 919-931.
41. Brandt, I., Joossens, J., Chen, X., Maes, M. B., Scharpe, S., De Meester, I., and Lambeir, A. M. (2005) Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino] acetyl}-pyrrolidine-2-carbon-itrile). Biochem. Pharmacol. 70, 134-143.
42. Kim, Y. B., Kopcho, L. M., Kirby, M. S., Hamann, L. G., Weigelt, C. A., Metzler, W. J., and Marcinkeviciene, J. (2006) Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch. Biochem. Biophys. 445, 9-18.
43. Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., Han, S. P., Abboa-Offei, B., Cap, M., Xin, L., Tao, L., Tozzo, E., Welzel, G. E., Egan, D. M., Marcinkeviciene, J., Chang, S. Y., Biller, S. A., Kirby, M. S., Parker, R. A., and Hamann, L. G. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025-5037.
44. Kapur, S., and Seeman, P. (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25, 161-166.
45. Seeman, P. (2006) Targeting the dopamine D2 receptor in schizophrenia 1. Expert Opin. Ther. Targets 10, 515-531.
46. Ward, W. H., Holdgate, G. A., Rowsell, S., McLean, E. G., Pauptit, R. A., Clayton, E., Nichols, W. W., Colls, J. G., Minshull, C. A., Jude, D. A., Mistry, A., Timms, D., Camble, R., Hales, N. J., Britton, C. J., and Taylor, I. W. (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38, 12514-12525.
47. Lovmar, M., Tenson, T., and Ehrenberg, M. (2004) Kinetics of macrolide action: The josamycin and erythromycin cases. J. Biol. Chem. 279, 53506-53515.
48. Anthes, J. C., Gilchrest, H., Richard, C., Eckel, S., Hesk, D., West, R. E., Jr., Williams, S. M., Greenfeder, S., Billah, M., Kreutner, W., and Egan, R. E. (2002) Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. J. Pharmacol. 449, 229-237.
49. Maillard, M. P., Perregaux, C., Centeno, C., Stangier, J., Wienen, W., Brunner, H. R., and Burnier, M. (2002) In vitro and in vivo characterization of the activity of telmisartan: An insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 302, 1089-1095.
50. Dowling, M. R., and Charlton, S. J. (2006) Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br. J. Pharmacol. 148, 927-937.
51. Disse, B., Reichl, R., Speck, G., Traunecker, W., Ludwig Rominger, K. L., and Hammer, R. (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52, 537-544.
52. Karlsson, R., Katsamba, P. S., Nordin, H., Pol, E., and Myszka, D. G. (2006) Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349, 136-147.
53. Stone, S. R., and Hofsteenge, J. (1986) Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25, 4622-4628.
54. Taketomi, T., Szlam, F., Vinten-Johansen, J., Levy, J. H., and Tanaka, K. A. (2007) Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagulation Fibrinolysis 18, 761-767.
55. Leysen, J. E., Gommeren, W., Van Gompel, P., Wynants, J., Janssen, P. F., and Laduron, P. M. (1985) Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 27, 600-611.
56. Seeman, P. (2005) Au update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry 162, 1984-1985.
57. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Home, E., Lackey, K., Alligood, K. J., Rusnak, D. W., Gilmer, T. M., and Shewchuk, L. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659.
58. Gooljarsingh, L. T., Fernandes, C., Yan, K., Zhang, H., Grooms, M., Johanson, K., Sinnamon, R. H., Kirkpatrick, R. B., Kerrigan, J., Lewis, T., Arnone, M., King, A. J., Lai, Z., Copeland, R. A., and Tummino, P. J. (2006) A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl. Acad. Sci. U.S.A. 103, 7625-7630.
59. Hale, J. J., Mills, S. G., MacCoss, M., Finke, P. E., Cascieri, M. A., Sadowski, S., Ber, E., Chicchi, G. G., Kurtz, M., Metzger, J., Eiermann, G., Tsou, N. N., Tattersall, F. D., Rupniak, N. M., Williams, A. R., Rycroft, W., Hargreaves, R., and MacIntyre, D. E. (1998) Structural optimization affording 2-(R)-(1-(R)-3,5-bis(tri-fluoromethyl)phenylethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. 41, 4607-4614.
60. Bull, H. G. G.-C. M., Andersson, S., Baginsky, W. F., Chan, H. K., Ellsworth, D. E., Miller, R. R., Stearns, R. A., Bakshi, R. K., Rasmusson, G. H., Tolman, R. L., Myers, R. W., Kozarich, J. W., and Harris, G. S. (1996) Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. J. Am. Chem. Soc. 118, 2359-2365.
61. Kohout, T. A., Xie, Q., Reijmers, S., Finn, K. J., Guo, Z., Zhu, Y. F., and Struthers, R. S. (2007) Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism. Mol. Pharmacol. 72, 238-247.
62. Sullivan, S. K., Hoare, S. R., Fleck, B. A., Zhu, Y. F., Heise, C. E., Struthers, R. S., and Crowe, P. D. (2006) Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism. Biochem. Pharmacol. 72, 838-849.
63. Fersht, A. (1985) Enzyme Structure and Mechanism, pp 150-151, Freeman, New York.